The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Oncology Molecular Diagnostics Market Over The Period 2026–2030?
The oncology molecular diagnostics market has experienced significant expansion recently. It is projected to grow from $5.65 billion in 2025 to $6.34 billion in 2026, at a compound annual growth rate (CAGR) of 12.2%. This historic growth can be attributed to factors such as increasing cancer prevalence, the adoption of PCR and sequencing technologies, oncology research funding, the expansion of hospital diagnostic capabilities, and regulatory approvals for molecular tests.
The oncology molecular diagnostics market is projected to experience swift expansion over the coming years. Its valuation is anticipated to reach $10.13 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.4%. This expansion during the forecast period stems from factors such as increased adoption of precision oncology, progress in liquid biopsy techniques, the rising need for personalized treatments, AI-powered data analysis, and deeper penetration into new markets. Key trends for this period encompass the development of companion diagnostics, the escalating application of liquid biopsy, broadening of biomarker-based testing, an uptick in cancer screening initiatives, and the ongoing need for prompt and precise cancer detection.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3457&type=smp
What Underlying Factors Are Accelerating The Growth Of The Oncology Molecular Diagnostics Market?
The anticipated expansion of the oncology molecular diagnostics market is primarily fueled by the growing requirement for personalized medicine. This innovative healthcare strategy involves customizing medical decisions, practices, interventions, and drug therapies specifically for each patient. Within the context of personalized medicine for cancer patients, oncology molecular diagnostics play a crucial role by enabling tailored treatment plans, better drug selection, and more accurate, impactful, and individualized treatment approaches, thereby enhancing patient results and overall quality of life. As an example, the Personalized Medicine Coalition, a US-based nonprofit organization, disclosed in February 2024 that the FDA cleared 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the rising need for personalized medicine serves as a key impetus for the expansion of the oncology molecular diagnostics market.
How Is The Oncology Molecular Diagnostics Market Divided Into Its Major Segments?
The oncology molecular diagnostics market covered in this report is segmented –
1) By Product: Instruments, Reagents, Other Products
2) By Technology: Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips And Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies
3) By End User: Hospitals, Diagnostic Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, Microarray Platforms, Fluorescence In Situ Hybridization (FISH) Instruments
2) By Reagents: DNA And RNA Extraction Kits, PCR Reagents And Kits, NGS Library Preparation Kits, Diagnostic Assay Reagents
3) By Other Products: Software For Data Analysis And Interpretation, Quality Control And Calibration Products, Consumables, For Molecular Testing, Biomarkers For Oncology Testing
How Are Trends Transforming The Oncology Molecular Diagnostics Market Landscape?
Leading companies operating within the oncology molecular diagnostics market are concentrating on advancing genomics technologies, including next-generation cancer genome sequencing, computational analytics, and innovative tumor modeling. These efforts aim to enhance early cancer detection, refine mutation identification, and improve personalized treatment strategies. Such developments boost diagnostic precision, decrease turnaround times, and cater to the increasing demand for localized, highly accurate molecular testing. For example, in May 2024, OncoHelix-CoLab, a Canada-based precision oncology provider specializing in genomic and immunologic profiling, advanced molecular diagnostics, and immune-profile testing, inaugurated a cutting-edge laboratory at Burjeel Medical City in the UAE. This facility, established through a partnership between Burjeel Holdings and OncoHelix, strengthens regional diagnostic capabilities by enabling complex molecular and immunology tests to be conducted locally rather than being sent abroad. Its specialized services feature advanced assays for various cancers, such as prostate cancer, supported by collaborations like its partnership with Nanostics for the ClarityDX Prostate test.
Who Are The Prominent Organizations Shaping The Oncology Molecular Diagnostics Market?
Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.
Read the full oncology molecular diagnostics market report here:
Which Region Is Projected To Dominate The Oncology Molecular Diagnostics Market During The Forecast Period?
North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the oncology molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Oncology Molecular Diagnostics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3457&type=smp
Browse Through More Reports Similar to the Global Oncology Molecular Diagnostics Market 2026, By The Business Research Company
Diagnostic Imaging Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/diagnostic-imaging-equipment-global-market-report
Diagnostic And Monitoring Ophthalmic Devices And Equipment Market Report 2026
Microbiology Diagnostic Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model